Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $521.36M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 4.00M
Average 3.76M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
CRISPR Therapeutics AG NASDAQ:CRSP | $4.10B | $42.24 | Not rated | -9.2 | -21.02% |
Legend Biotech Corporation NASDAQ:LEGN | $3.24B | $17.50 | Not rated | -21.4 | -41.52% |
Beam Therapeutics Inc. NASDAQ:BEAM | $2.36B | $22.83 | Not rated | -52.3 | +1.65% |
Intellia Therapeutics, Inc. NASDAQ:NTLA | $1.36B | $9.70 | Not rated | -4.6 | +18.41% |
Cullinan Therapeutics, Inc. NASDAQ:CGEM | $667.39M | $10.28 | Not rated | -4.0 | +4.01% |
Century Therapeutics, Inc. NASDAQ:IPSC | $298.77M | $1.65 | Not rated | -1.8 | +169.00% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $290.58M | $0.84 | Not rated | -2.7 | -46.22% |
Precision BioSciences, Inc. NASDAQ:DTIL | $211.33M | $7.57 | Not rated | -1.9 | +38.76% |
Fate Therapeutics, Inc. NASDAQ:FATE | $149.20M | $1.28 | Not rated | -1.8 | +1.00% |
Atara Biotherapeutics, Inc. NASDAQ:ATRA | $78.45M | $7.70 | Not rated | -14.7 | -52.04% |
Continue the stock analysis
Jump to another research area for this company.